ÂÜÀòÂÒÂ×

Matyas Lakatos is an experienced biopharmaceutical leader specializing in project and marketing strategies within the industry. Currently serving as Project Vice President for Rybelsus at Novo Nordisk, Matyas has been instrumental in developing lifecycle strategies for oral semaglutide. Prior roles include Vice President of Global Marketing for Ozempic and Victoza, where Matyas transformed diabetes treatment approaches. With a background in pharma strategy consulting and significant leadership positions at Takeda, Amgen, and Schering Plough, Matyas has a proven track record in driving market growth and launching innovative therapies across various therapeutic areas, including oncology and autoimmune diseases. Educational qualifications include an M.B.A. from La Salle University and an MD from the University of Zurich.